Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK2 | Q9HBH9 | 5/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 13/20 | 0.36 |
| ▸ | NTRK3 | Q16288 | 8/20 | 0.36 |
| ▸ | NTRK2 | Q16620 | 6/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20359956 | 0.90 | NTRK1 (0.43) | MKNK2NTRK1NTRK3NTRK2 | |
| SCHEMBL21815180 | 0.90 | NTRK1 (0.43) | MKNK2NTRK1NTRK3NTRK2 | |
| SCHEMBL20359954 | 0.90 | NTRK1 (0.43) | MKNK2NTRK1NTRK3NTRK2 | |
| SCHEMBL16946813 | 0.90 | NTRK1 (0.43) | MKNK2NTRK1NTRK3NTRK2 | |
| SCHEMBL18361487 | 0.88 | MKNK2 (0.38) | MKNK2NTRK1NTRK3NTRK2IRAK4 | |
| SCHEMBL18361486 | 0.87 | NTRK1 (0.37) | MKNK2NTRK1NTRK3NTRK2IRAK4 | |
| SCHEMBL18361488 | 0.87 | NTRK1 (0.38) | MKNK2NTRK1NTRK3NTRK2IRAK4 | |
| SCHEMBL31250788 | 0.83 | NTRK1 (0.44) | NTRK1NTRK3NTRK2PCSK9 | |
| SCHEMBL18361545 | 0.83 | NTRK1 (0.43) | NTRK1NTRK3NTRK2 | |
| SCHEMBL18361450 | 0.83 | NTRK1 (0.44) | NTRK1NTRK3NTRK2PCSK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11008337-B2 | Chiral diaryl macrocycles as modulators of protein kinases | Turning Point Therapeutics, Inc. (US) | 2021-05-18 | — | — | US | disclosed |
| US-20190284209-A1 | CHIRAL DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | Turning Point Therapeutics, Inc. | 2019-09-19 | — | — | US | disclosed |
| US-20180186813-A1 | CHIRAL DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | Turning Point Therapeutics, Inc. | 2018-07-05 | — | — | US | disclosed |
| WO-2017004342-A1 | CHIRAL DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | TP THERAPEUTICS, INC. (US) | 2017-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180186813-A1 | CHIRAL DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | MAP3K20, LCK, DAPK2 | MKNK2 109/4885NTRK1 1462/4885NTRK3 2203/4885 |
| US-20190284209-A1 | CHIRAL DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | MAP3K20, LCK, DAPK2 | MKNK2 109/4885NTRK1 1462/4885NTRK3 2203/4885 |
| US-11008337-B2 | Chiral diaryl macrocycles as modulators of protein kinases | LCK, MAP3K20, MAP3K19 | MKNK2 131/4885NTRK1 1409/4885NTRK3 2017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.